(A, B) qPCR assays for Nlrp6 (A) and Nlrp9b (B) mRNA levels in different locations of the intestine relative to the Hprt control. Mean ± SEM for 6 mice is displayed for each group.
(C, D) Immunoblotting of IEC lysates of multiple WT and Nlrp6−/− mice for caspase-1 (C) and GSDMD (D).
(E) IL-18 levels of intestine explant supernatant of WT and Nlrp6−/− mice determined by ELISA. Mean ± SEM for 5 mice is displayed for each group.
(F) Immunoblotting of IEC lysates of 3 WT and K350–354A mutant mice each for GSDMD processing.
(G) IL-18 levels of intestine explant supernatant of WT and K350–354A mutant mice determined by ELISA. Mean ± SEM for 4 WT and 6 mutant mice is displayed for each group.
(H) Immunoblot of 3 small intestine homogenates each from mock or RV-infected WT and Nlrp6−/− mice 2 days post RV infection to detect cleaved GSDMD.
(I) Intestine-explant supernatant IL-18 levels in WT and Nlrp6−/− mice 2 days post-infection.
(J) Immunoblot of 3 small intestine homogenates each from mock or RV-infected WT and K350–354A mutant mice 2 days post RV infection to detect cleaved GSDMD.
(K) Intestine-explant supernatant IL-18 levels in WT and K350–354A mutant mice 2 days post-infection.